NETRF Announces Changes to its Board of Scientific Advisors

NETRF is thrilled to announce that Chrissie Thirlwell, MD, PhD, will serve as the new Co-Chair of the NETRF Board of Scientific Advisors (BOSA) beginning in January 2022. She will be replacing Dr. George Fisher, who has served as CoChair with Dr. Daniel Chung, since 2016 and is stepping down from the position this year. Dr. Thirlwell is renowned for advancing NET research, the clinical management of NETs and the integrated genomic analysis of cancer. She has published over 20 primary research papers on NETs and been awarded over a dozen grants focusing on NET research. Dr. Thirlwell has participated on many clinical and research committees and been invited to present and Chair sessions at national and international NET conferences. She is the recipient of numerous awards for her contributions to the advancement of NET research and most recently has accepted a prestigious role in the UK as the Director of  Genomic Medicine.  

Dr. Thirlwell was appointed the Mireille Gillings Professor of Cancer Genomics, in the College of Medicine and Health and Institute of Biomedical and Clinical Science in 2019. Prior to this she was a Senior Lecturer and Consultant Medical Oncologist at the University College of London Cancer Institute and Royal Free Hospital, and lead Consultant on the multi-disciplinary neuroendocrine tumor and hepatocellular cancer teams.  She also leads the Neuroendocrine tumor 100,000 genomes GeCIP and is the Cancer arm representative on the 100,000 genomes GeCIP Board. Dr. Thirlwell looks forward to the new NETRF role saying, “I have received support, mentorship and opportunities to collaborate through NETRF since 2008. It’s been a great honor to serve on the NETRF BOSA since 2016 which brings together a fantastic group of scientists and clinicians, all focused on improving outcomes for NET patients globally.” NETRF welcomes Dr. Thirlwell who will be joining Dr. Dawn Quelle to Co-Chair the BOSA and helping NETRF advance its mission to accelerate NET research and therapeutic development. We also thank Dr. George Fisher for his service and leadership as co-chair during the past five years.